Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Executive Summary
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
You may also be interested in...
Novartis MS Therapy FTY720 Enters Phase III With Lower, Untested Dose
Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy
Amgen To Re-Launch AMG 706 Phase II Enrollment, Phase III Still Delayed
Amgen will re-launch enrollment of head-to-head Phase II studies for its oncologic AMG 706 after concerns were raised about the potential development of cholecystitis, although the Phase III trials remain indefinitely delayed
Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters